Top Page
Oxford BioDynamics
(LSE:OBD)
Oxford BioDynamics (OBD) vs. S&P 500 (SPY)
Oxford BioDynamics Business Overview & Revenue Model
Oxford BioDynamics Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 617.00K | 636.00K | 510.00K | 154.00K | 341.00K | 456.00K | Gross Profit |
| -7.49M | 289.00K | 266.00K | 116.00K | -557.00K | -166.00K | EBIT |
| -12.43M | -12.89M | -11.03M | -8.60M | -7.51M | -4.95M | EBITDA |
| -9.32M | -10.27M | -9.84M | -6.16M | -6.43M | -4.42M | Net Income Common Stockholders |
| -11.11M | -11.57M | -10.83M | -6.71M | -6.68M | -4.31M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.19M | 2.83M | 5.25M | 999.00K | 4.34M | 11.51M | Total Assets |
| 11.07M | 12.11M | 16.13M | 11.34M | 15.38M | 15.35M | Total Debt |
| 6.00M | 5.74M | 6.44M | 6.14M | 6.59M | 541.00K | Net Debt |
| 4.82M | 3.91M | 1.19M | 5.16M | 4.41M | -5.58M | Total Liabilities |
| 9.44M | 7.75M | 10.07M | 8.76M | 8.69M | 1.77M | Stockholders Equity |
| 1.62M | 4.36M | 6.05M | 2.59M | 6.68M | 13.56M |
| Cash Flow | Free Cash Flow | ||||
| -7.46M | -10.77M | -9.01M | -6.08M | -9.01M | -3.86M | Operating Cash Flow |
| -6.71M | -10.17M | -8.29M | -5.18M | -5.92M | -3.40M | Investing Cash Flow |
| 1.68M | -1.49M | -691.00K | 1.25M | 2.83M | 4.58M | Financing Cash Flow |
| 5.03M | 8.25M | 13.42M | 2.56M | -804.00K | -181.00K |
Oxford BioDynamics Technical Analysis
Oxford BioDynamics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £8.57M | ― | -19.15% | ― | -13.49% | -69.67% | |
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
49 Neutral | £6.97M | ― | -99.43% | ― | 17.39% | 96.02% | |
46 Neutral | £15.48M | ― | -137.62% | ― | 10.50% | -9.60% | |
44 Neutral | £7.34M | ― | -222.16% | ― | 24.71% | 38.28% | |
44 Neutral | £7.67M | ― | -129.49% | ― | 14.12% | 78.16% |
Oxford BioDynamics Corporate Events
Oxford BioDynamics has announced that its Oxford-based laboratory has been accredited by the United Kingdom Accreditation Service (UKAS) under the ISO 15189 standard, allowing it to conduct EpiSwitch® Clinical Tests in the UK. This accreditation marks a significant milestone for the company, as it enhances the turnaround time for test results and supports the company’s strategy to centralize its clinical testing operations in the UK. The successful validation of the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) in the UK lab is expected to benefit cancer patients by reducing the time taken to receive test results, thereby strengthening the company’s position in the diagnostics industry and its relationship with partners like Bupa UK.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Neutral.
Oxford BioDynamics exhibits significant financial and technical challenges, with persistent net losses, increasing leverage, and weak technical indicators. However, positive corporate events, such as insider buying and strategic partnerships, provide some optimism. The overall score reflects the need for substantial financial and operational improvements despite positive developments in corporate activities.
To see Spark’s full report on GB:OBD stock, click here.
Oxford BioDynamics announced that Non-Executive Director Peter Presland has purchased 3,398,553 ordinary shares, representing approximately 0.17% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s future prospects and could positively influence stakeholder perceptions and market positioning.
Spark’s Take on GB:OBD Stock
According to Spark, TipRanks’ AI Analyst, GB:OBD is a Underperform.
Oxford BioDynamics exhibits significant financial challenges with negative profitability and cash flow issues, compounded by technical weakness in stock performance. Despite positive corporate developments and strategic partnerships, the fundamental financial weaknesses and technical indicators weigh heavily on the overall score.
To see Spark’s full report on GB:OBD stock, click here.
Oxford BioDynamics Plc announced a transaction involving its CFO, Paul Stockdale, who transferred 791,176 ordinary shares into his ISA through a sale and repurchase process. This transaction, conducted on the London Stock Exchange, leaves Stockdale with a beneficial interest in 3,077,919 shares, representing 0.16% of the company’s issued share capital. This move is part of routine financial management and does not indicate any significant change in company operations or strategy.
Oxford BioDynamics Plc announced the successful passing of all resolutions at its Annual General Meeting. This development underscores the company’s continued commitment to advancing precision medicine through its innovative diagnostic tests, potentially enhancing its market position and stakeholder confidence.
Oxford BioDynamics has announced the appointment of Peter Presland as a Non-Executive Director and Chair of the Audit Committee, succeeding Matthew Wakefield. Presland brings extensive experience in business management and corporate governance, which is expected to enhance the board’s independence and governance capabilities. This strategic board change is anticipated to positively impact the company’s operational and governance structure, potentially benefiting stakeholders by strengthening the company’s leadership and oversight.
Oxford BioDynamics PLC has announced a change in its major holdings, with Spreadex LTD acquiring or disposing of financial instruments, resulting in a shift in voting rights. The transaction has led to a decrease in the total percentage of voting rights held by Spreadex LTD, which could impact the company’s influence on corporate decisions and its strategic positioning within the industry.
Oxford BioDynamics has expanded its partnership with Bupa UK insurance to include coverage for its EpiSwitch® PSE prostate cancer test. This strategic agreement enhances access to the PSE test for Bupa’s 3.9 million customers, particularly those with raised PSA levels but no high-risk factors or symptoms. The PSE test, known for its high accuracy and positive predictive value, aims to improve early prostate cancer diagnosis and reduce unnecessary procedures, aligning with Bupa’s commitment to advanced cancer care.
Oxford BioDynamics Plc has published its 2024 Annual Report, available on its website, detailing its financial results and operations for the year. The report’s release comes ahead of the company’s Annual General Meeting scheduled for March 28, 2025. This announcement underscores the company’s ongoing commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
Oxford BioDynamics has announced the granting of 218 million share options to its employees and advisers, including key directors and PDMRs, under its 2016 Employee and Non-Employee Share Option Plans. This move, with an exercise price set at the previous closing share price, aims to align the interests of the management with those of the shareholders, potentially impacting the company’s market positioning and stakeholder engagement.
Oxford BioDynamics Plc announced its preliminary results for the year ending September 2024, highlighting significant corporate and operational developments. The company achieved a CPT-PLA Code for its EpiSwitch PSE Test, enabling reimbursement by US insurers, and opened a UK Clinical Laboratory. Despite an operating loss of £12.9m, the company raised substantial funds to support its ongoing operations. Post-year-end, Oxford BioDynamics secured a distribution agreement with Romania’s largest private healthcare provider and presented real-world data on its EpiSwitch CiRT at a major conference. The company plans to focus on partnerships and collaborations to enhance commercial success and shareholder value.
Oxford BioDynamics Plc announced it will release its financial results for the year ending September 30, 2024, on February 28, 2025. The announcement signifies a crucial update for stakeholders as it reflects the company’s operational performance and strategic positioning within the precision diagnostics industry. The company is known for its innovative genomics platform that enhances diagnostic precision and treatment predictions, supporting its market position and potential growth.
Oxford BioDynamics PLC has announced a significant change in its voting rights structure following the acquisition by Sankofa Strategic Equity Fund Limited. The fund, based in Guernsey, has acquired a 6.57% stake in the company, signaling a notable shift in its shareholder composition. This development could impact the company’s operations by potentially influencing decision-making processes and strategic directions, with implications for stakeholders and market positioning.